|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
381,510,000 |
Market
Cap: |
169.20(M) |
Last
Volume: |
4,513,016 |
Avg
Vol: |
4,500,752 |
52
Week Range: |
$0.4435 - $2.04 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Agenus is a clinical-stage immuno-oncology (I-O) company engaged in the development of a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer and infections. Co.'s antibody candidates are balstilimab (an anti-PD-1 antibody) and zalifrelimab (an anti-CTLA-4 antibody), which are in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Co. is also developing an anti-CTLA-4 antibody, botensilimab (also known as AGEN1181), which is designed to improve the magnitude of responses to first-generation anti-CTLA-4 molecules.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
500,000 |
525,000 |
525,000 |
Total Buy Value |
$0 |
$324,050 |
$343,050 |
$343,050 |
Total People Bought |
0 |
1 |
2 |
2 |
Total Buy Transactions |
0 |
1 |
2 |
2 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Valentine Karen |
VP, General Counsel |
|
2012-01-26 |
4 |
A |
$2.76 |
$1,151 |
D/D |
417 |
16,816 |
|
- |
|
Sharp Shalini |
CFO |
|
2012-01-26 |
4 |
A |
$2.76 |
$1,725 |
D/D |
625 |
64,390 |
|
- |
|
Armen Garo H |
Chairman & CEO |
|
2012-01-26 |
4 |
A |
$2.76 |
$3,834 |
D/D |
1,389 |
933,681 |
|
- |
|
Klaskin Christine M |
VP, Finance |
|
2012-01-26 |
4 |
A |
$2.76 |
$1,151 |
D/D |
417 |
18,363 |
|
- |
|
Wentworth Kerry |
VP, Clinical, Reg, & Quality |
|
2012-01-03 |
4 |
A |
$2.17 |
$48,003 |
D/D |
22,121 |
37,599 |
|
- |
|
Valentine Karen |
VP, General Counsel |
|
2012-01-03 |
4 |
A |
$2.17 |
$33,001 |
D/D |
15,208 |
16,399 |
|
- |
|
Sharp Shalini |
CFO |
|
2012-01-03 |
4 |
A |
$2.17 |
$48,003 |
D/D |
22,121 |
63,765 |
|
- |
|
Klaskin Christine M |
VP, Finance |
|
2012-01-03 |
4 |
A |
$2.17 |
$27,752 |
D/D |
12,789 |
17,946 |
|
- |
|
Armen Garo H |
Chairman & CEO |
|
2012-01-03 |
4 |
A |
$2.27 |
$13,200 |
D/D |
5,826 |
932,292 |
|
- |
|
Wentworth Kerry |
VP, Clinical, Reg, & Quality |
|
2011-12-29 |
4 |
S |
$2.01 |
$17,967 |
D/D |
(8,939) |
15,478 |
|
- |
|
Valentine Karen |
VP, General Counsel |
|
2011-12-29 |
4 |
S |
$1.98 |
$15,058 |
D/D |
(7,605) |
1,191 |
|
- |
|
Wentworth Kerry |
VP, Clinical, Reg, & Quality |
|
2011-12-28 |
4 |
S |
$2.09 |
$3,956 |
D/D |
(1,893) |
24,417 |
|
- |
|
Valentine Karen |
VP, General Counsel |
|
2011-12-28 |
4 |
S |
$2.09 |
$2,719 |
D/D |
(1,301) |
8,796 |
|
- |
|
Sharp Shalini |
CFO |
|
2011-12-28 |
4 |
S |
$2.09 |
$3,576 |
D/D |
(1,711) |
41,644 |
|
- |
|
Wentworth Kerry |
VP, Clinical, Reg, & Quality |
|
2011-12-27 |
4 |
S |
$2.14 |
$6,754 |
D/D |
(3,156) |
26,309 |
|
- |
|
Valentine Karen |
VP, General Counsel |
|
2011-12-27 |
4 |
S |
$2.14 |
$4,642 |
D/D |
(2,169) |
10,097 |
|
- |
|
Sharp Shalini |
CFO |
|
2011-12-27 |
4 |
S |
$2.14 |
$6,105 |
D/D |
(2,853) |
43,355 |
|
- |
|
Wentworth Kerry |
VP, Clinical, Reg, & Quality |
|
2011-12-23 |
4 |
S |
$2.20 |
$1,947 |
D/D |
(886) |
29,465 |
|
- |
|
Valentine Karen |
VP, General Counsel |
|
2011-12-23 |
4 |
S |
$2.20 |
$1,336 |
D/D |
(608) |
12,266 |
|
- |
|
Sharp Shalini |
CFO |
|
2011-12-23 |
4 |
S |
$2.20 |
$1,747 |
D/D |
(795) |
46,208 |
|
- |
|
Klaskin Christine M |
VP Finance |
|
2011-12-23 |
4 |
S |
$2.20 |
$1,123 |
D/D |
(511) |
14,468 |
|
- |
|
Wentworth Kerry |
VP, Clinical, Reg, & Quality |
|
2011-12-22 |
4 |
S |
$2.19 |
$3,759 |
D/D |
(1,716) |
30,351 |
|
- |
|
Valentine Karen |
VP, General Counsel |
|
2011-12-22 |
4 |
S |
$2.19 |
$2,578 |
D/D |
(1,177) |
12,874 |
|
- |
|
Sharp Shalini |
CFO |
|
2011-12-22 |
4 |
S |
$2.19 |
$3,391 |
D/D |
(1,548) |
47,003 |
|
- |
|
Klaskin Christine M |
VP Finance |
|
2011-12-22 |
4 |
S |
$2.19 |
$2,175 |
D/D |
(993) |
14,979 |
|
- |
|
537 Records found
|
|
Page 12 of 22 |
|
|